argenx is commited to serving patients who have unmet medical needs and to closing scientific gaps to improve patient care. To help meet these needs, argenx supports externally sponsored research (ESR) programs.
argenx welcomes unsolicited proposal from a broad range qualified sponsors with clinical hypotheses in areas of stragegic interest and priority. Unsolicited proposals will be reviewed by a cross-functional medical and scientific team to ensure they are based on scientifically sound principles that are intended to provide scientific and/or clinical information valuable to argenx and the medical community, and that could serve to improve patient care.
Overview of the Program
ESR is research that is initiated by a non-argenx researcher who submits an unsolicited request to argenx for support needed to perform an independent research study.
Requested support can be monetary funding and/or argenx materials to support the execution of the study.
ESR does not include independent medical education grants, sponsorships, or charitable contributions.
ESR Funding will be considered for:
- Clinical studies of argenx products that are approved by regulatory authorities for their approved indication, and products and/or areas of interest.
- Clinical observational studies including real-world evidence (RWE) research that can increase the understanding of argenx product(s) in patient with specific unmet medical needs
- Interventional studies that can enhance the understanding of the effect of argenx product(s) that can further define mechanisms of action, enhance the understanding of clinical differentiation, and other exploratory clinical hypothesis.
- Note, priority will be placed on submissions for an approved argenx product(s) for its approved indication(s)
ESR Funding will not be provided for:
- Research that has already been performed or is not required
- To defray the requestor's ordinary operating expenses
- Studies that do not align with the argenx strategy for scientific priorities
- Access to investigational product(s) through compassionate use or expanded accesss
